Comparison of the Efficacy and Safety of 2 Regimens of Taxotere Combined with Epirubicin in the Neoadju-vant Chemotherapy of Breast Cancer
10.6039/j.issn.1001-0408.2015.24.11
- VernacularTitle:2种多西他赛联合表柔比星方案新辅助化疗乳腺癌疗效与安全性的比较
- Author:
Lan JIANG
;
Wenbing HU
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Neoadjuvant chemotherapy;
Taxotere;
Epirubicin;
Efficacy;
Safety
- From:
China Pharmacy
2015;(24):3340-3341,3342
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the short-term efficacy and toxicity reaction of 2 regimens of taxotere combined with epi-rubicin in the neoadjuvant chemotherapy of breast cancer. METHODS:78 patients with locally advanced breast cancer were random-ly divided into TEC group(45 cases)and TE group(33 cases). TEC group was treated with taxotere 75 mg/m2 by intravenous in-jection,d1+epirubicin 60 mg/m2 by intravenous injection,d1+cyclophosphamide 500 mg/m2 by intravenous injection d1. TE group was treated with taxotere 75 mg/m2 by intravenous injection,d1+epirubicin 60 mg/m2 by intravenous injection,d1. 21 days were a treatment course for 2 groups,and there were totally 4-6 courses. In the 2 groups,efficacy and toxicity reaction were evaluated af-ter 4 weeks at least,and survival rate of 6 months was followed-up. RESULTS:The differences were not statistically significant in the short-term efficacy and toxicity reaction and survival rate between 2 groups (P>0.05). CONCLUSIONS:TEC and TC have similar short-term efficacy and safety in the treatment of locally advanced breast cancer. Both of them can be used as adjuvant medi-cines for neoadjuvant chemotherapy.
